LAUSR

Tricuspid regurgitation (TR) is mostly secondary to annular dilatation and/or leaflet tethering, in the absence of organic valve lesions or, as a result of left-sided heart valve disease, atrial fibrillation, or pulmonary hypertension, [functional TR (FTR)]. Isolated tricuspid surgery is usually carried out with a very high morbidity and mortality, resulting in a large number of untreated patients. Percutaneous procedures have been emerging as an attractive alternative to surgery. Although feasibility has been shown with several devices, clinical experience is still very preliminary and only limited data are available to support any evidence of clinical efficacy. This review will summarize the specific challenges of transcatheter tricuspid valve interventions (TTVI) and the available technologies which are currently under evaluation.